No specific information is available on the treatment of overdosage with montelukast. In chronic asthma studies, montelukast has been administered at doses up to 200 mg per days to adult patients for 22 weeks and in short-term studies, up to 900 mg per day to patients for approximately one week to without clinically important adverse experiences. There have been reports of acute overdosage in postmarketing experience and clinical studies with montelukast. These includes reports in adults and children with a dose as high as 1000 mg. the clinical and laboratory findings observed were consistent with the safety profile in adults and pediatric patients. There were no adverse experiences reported in the majority of overdosage reports. The most frequent occurring adverse experiences were consistent with the safety profile of montelukast and included abdominal pain, somnolence, thirst, headache, vomiting and psychomotor hyperactivity. It is not known whether montelukast is dialyzable by peritoneal or hemodialysis.
Sign Out
